AutoImmune Inc. Reports 2008 Fourth Quarter and Year End Financi...(---- ---- Revenue ...)

Date:3/16/2009

---- ---- Revenue $75,000 $91,000 $294,000 $316,000 ------- ------- -------- -------- Costs and expenses: Cost of revenue 1,000 16,000 21,000 45,000 Research and development 49,000 81,000 144,000 174,000 Selling, general and administrative 181,000 136,000 713,000 647,000 ------- ------- ------- ------- Total costs and expenses 231,000 233,000 878,000 866,000 ------- ------- ------- ------- Interest income 105,000 18,000 440,000 213,000 Minority interest in joint venture (5,000) (5,000) 1,000 (8,000) Other income - - 25,000 0 100,000 13,000 466,000 205,000 ------- ------ ------- ------- Net loss ($56,000) ($129,000) ($118,000) ($345,000) ======== ========= ========= ========= Net loss per share - basic $0.00 ($0.01) ($0.01) ($0.02) ===== ====== ====== ====== Net loss per share - diluted $0.00 ($0.01) ($0.01) ($0.02) ===== ====== ====== ====== Weighted average common shares outstanding - basic 16,979,623 16,999,623 16,970,558 16,999,022 ========== ========== ========== ========== Weighted average common shares outstanding - diluted 16,979,623 16,999,623 16,970,5
'/>"/>

SOURCE AutoImmune Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. Advances in Detection Technology Drive the European Autoimmune Disease Diagnostics Market
2. AutoImmune Inc. Reports 2008 Third Quarter Financial Results
3. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
4. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
5. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes - Correction
6. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes
7. Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results
8. Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
9. Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results
10. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results
11. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results